 SOUTH SAN FRANCISCO, Calif., May 26, 2021 GLOBE NEWSWIRE -- Day One Biopharmaceuticals, Inc. Nasdaq: DAWN, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of 16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be 160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol DAWN. The offering is expected to close on June 1, 2021, subject to the satisfaction of customary closing conditions. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. 